PIK3CA and neoplasm: Preclinically, neratinib inhibited proliferation in HER2-amplified, PIK3CA-mutant tumor cell lines [73], and inhibited tumor growth in a HER2-positive, PIK3CA-mutant patient-derived xenograft model [119].